Rocket Pharmaceuticals (RCKT) Stock Statistics & Valuation Metrics

Rocket Pharmaceuticals has a market cap or net worth of $575.80M. The enterprise value is $879.11M.

Rocket Pharmaceuticals has 106.63M shares outstanding. The number of shares has decreased by -2.65% in one year.

Rocket Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -55.77%.

The current PE Ratio of Rocket Pharmaceuticals is -4.61. Rocket Pharmaceuticals’s PEG ratio is 0.71.

In the last 12 months, Rocket Pharmaceuticals had revenue of $0.00 and earned -$258.75M in profits. Earnings per share was -$2.73.

In the last 12 months, operating cash flow was -$209.78M and capital expenditures -$5.86M, giving a free cash flow of -$215.64M billion.

Rocket Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of

Rocket Pharmaceuticals upcoming earnings date is May 7, 2025, Before Open.

Rocket Pharmaceuticals as a current ratio of 9.30, with Debt / Equity ratio of 0.06

In the past 12 months, Rocket Pharmaceuticals has paid $1.00 in taxes.

Rocket Pharmaceuticals EV to EBITDA ratio is -3.86, with an EV/FCF ratio of -5.02.

Rocket Pharmaceuticals has $372.34M in cash and marketable securities with $25.50M in debt, giving a net cash position of -$346.84M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rocket Pharmaceuticals is $42.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy